210 related articles for article (PubMed ID: 19549254)
1. Expression of KAI1/CD82 in distant metastases from estrogen receptor-negative breast cancer.
Christgen M; Christgen H; Heil C; Krech T; Länger F; Kreipe H; Lehmann U
Cancer Sci; 2009 Sep; 100(9):1767-71. PubMed ID: 19549254
[TBL] [Abstract][Full Text] [Related]
2. KAI1/CD82 is a novel target of estrogen receptor-mediated gene repression and downregulated in primary human breast cancer.
Christgen M; Bruchhardt H; Ballmaier M; Krech T; Länger F; Kreipe H; Lehmann U
Int J Cancer; 2008 Nov; 123(10):2239-46. PubMed ID: 18712725
[TBL] [Abstract][Full Text] [Related]
3. KAI1/CD82 and MRP1/CD9 serve as markers of infiltration, metastasis, and prognosis in laryngeal squamous cell carcinomas.
Zhang BH; Liu W; Li L; Lu JG; Sun YN; Jin DJ; Xu XY
Asian Pac J Cancer Prev; 2013; 14(6):3521-6. PubMed ID: 23886139
[TBL] [Abstract][Full Text] [Related]
4. Down Regulation of KAI1/CD82 in Lymph Node Positive and Advanced T-Stage Group in Breast Cancer Patients.
Krishna Latha T; Verma A; Thakur GK; Banerjee B; Kaur N; Singh UR; Sharma S
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3321-3329. PubMed ID: 31759355
[TBL] [Abstract][Full Text] [Related]
5. miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
Endo Y; Toyama T; Takahashi S; Yoshimoto N; Iwasa M; Asano T; Fujii Y; Yamashita H
Endocr Relat Cancer; 2013 Feb; 20(1):91-102. PubMed ID: 23183268
[TBL] [Abstract][Full Text] [Related]
6. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients.
Huang CI; Kohno N; Ogawa E; Adachi M; Taki T; Miyake M
Am J Pathol; 1998 Sep; 153(3):973-83. PubMed ID: 9736046
[TBL] [Abstract][Full Text] [Related]
7. Expression and clinical significance of CD82/KAI1 and E-cadherin in non-small cell lung cancer.
Shiwu WU; Lan Y; Wenqing S; Lei Z; Yisheng T
Arch Iran Med; 2012 Nov; 15(11):707-12. PubMed ID: 23102249
[TBL] [Abstract][Full Text] [Related]
8. Limited value of KAI1/CD82 protein expression as a prognostic marker in human gastric cancer.
Knoener M; Krech T; Puls F; Lehmann U; Kreipe H; Christgen M
Dis Markers; 2012; 32(6):337-42. PubMed ID: 22684230
[TBL] [Abstract][Full Text] [Related]
9. Identifying CD82 (KAI1) as a marker for human chromophobe renal cell carcinoma.
Yusenko MV; Kovacs G
Histopathology; 2009 Dec; 55(6):687-95. PubMed ID: 20002769
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of the metastasis suppressor protein KAI1/CD82 correlates with occurrence of metastasis, prognosis and presence of HPV DNA in human penile squamous cell carcinoma.
Protzel C; Kakies C; Kleist B; Poetsch M; Giebel J
Virchows Arch; 2008 Apr; 452(4):369-75. PubMed ID: 18305955
[TBL] [Abstract][Full Text] [Related]
11. KAI1, a putative marker for metastatic potential in human breast cancer.
Yang X; Welch DR; Phillips KK; Weissman BE; Wei LL
Cancer Lett; 1997 Nov; 119(2):149-55. PubMed ID: 9570365
[TBL] [Abstract][Full Text] [Related]
12. Normal viability of Kai1/Cd82 deficient mice.
Risinger JI; Custer M; Feigenbaum L; Simpson RM; Hoover SB; Webster JD; Chandramouli GV; Tessarollo L; Barrett JC
Mol Carcinog; 2014 Aug; 53(8):610-24. PubMed ID: 23401136
[TBL] [Abstract][Full Text] [Related]
13. Re: KAI1/CD82 is a novel target of estrogen receptor-mediated gene repression and downregulated in primary human breast cancer (Int J Cancer 123: 2239-2246, 2008).
Geradts J
Int J Cancer; 2009 May; 124(9):2243-4; author reply 2245. PubMed ID: 19115215
[No Abstract] [Full Text] [Related]
14. Effect of expressional alteration of KAI1 on breast cancer cell growth, adhesion, migration and invasion.
Malik FA; Sanders AJ; Kayani MA; Jiang WG
Cancer Genomics Proteomics; 2009; 6(4):205-13. PubMed ID: 19656997
[TBL] [Abstract][Full Text] [Related]
15. OLFM4, LY6D and S100A7 as potent markers for distant metastasis in estrogen receptor-positive breast carcinoma.
Mayama A; Takagi K; Suzuki H; Sato A; Onodera Y; Miki Y; Sakurai M; Watanabe T; Sakamoto K; Yoshida R; Ishida T; Sasano H; Suzuki T
Cancer Sci; 2018 Oct; 109(10):3350-3359. PubMed ID: 30137688
[TBL] [Abstract][Full Text] [Related]
16. CD82/KAI1 inhibits invasion and metastasis of esophageal squamous cell carcinoma via TGF-β1.
Zeng TD; Zheng B; Zheng W; Chen C
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):5928-5937. PubMed ID: 30280774
[TBL] [Abstract][Full Text] [Related]
17. Decreased expression of KAI1/CD82 metastasis suppressor gene is associated with loss of heterozygosity in melanoma cell lines.
Kim YI; Shin MK; Lee JW; Chung JH; Lee MH
Oncol Rep; 2009 Jan; 21(1):159-64. PubMed ID: 19082457
[TBL] [Abstract][Full Text] [Related]
18. Expression and clinical significance of p53, JunB and KAI1/CD82 in human hepatocellular carcinoma.
Guo C; Liu QG; Zhang L; Song T; Yang X
Hepatobiliary Pancreat Dis Int; 2009 Aug; 8(4):389-96. PubMed ID: 19666408
[TBL] [Abstract][Full Text] [Related]
19. Reduced expression of the metastasis suppressor gene KAI1 in advanced colon cancer and its metastases.
Maurer CA; Graber HU; Friess H; Beyermann B; Willi D; Netzer P; Zimmermann A; Büchler MW
Surgery; 1999 Nov; 126(5):869-80. PubMed ID: 10568187
[TBL] [Abstract][Full Text] [Related]
20. Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases.
Friess H; Guo XZ; Berberat P; Graber HU; Zimmermann A; Korc M; Büchler MW
Int J Cancer; 1998 Aug; 79(4):349-55. PubMed ID: 9699525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
